Where to from here?, page-12

Patience brother, use these opportunities to accumulate if confident.
Nice little treat from the Annual Report:

Proteomics International will continue to pursue thecommercialisation of its lead diagnostic test, PromarkerDin global markets. Potential licence partners are global andregional diagnostic companies, diagnostic serviceproviders, and drug developers. In jurisdictions wherelicences have already been granted, the focus will be onincreasing the adoption of the test by engaging with KeyOpinion Leaders and the broader network of clinicalservice providers.

As for any novel test, market penetration cannot bepredicted accurately, hence for each licence it is notpossible to quantify the financial impact on ProteomicsInternational in any given timeframe. None the less,PromarkerD has the potential to spare millions of people from the cost of dialysis, saving each health care system billions of dollars. Consequently, the Company believes that ultimately the financial impact of each licence will be significant.The development pipeline for new diagnostic tests willprogress using the PromarkerTM technology platform, withthe intention of creating new intellectual property that canbe licensed in future years.

These R&D and commercialisation activities will continueto be underpinned by the analytical services operations.Fee-for-service revenue continues to grow and ProteomicsInternational anticipates further growth.